Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-02T21:42:12.790Z Has data issue: false hasContentIssue false
  • English
  • Français

Monitoring of tricyclic antidepressant plasma levels and clinical response: a review of the literature. Part II

Published online by Cambridge University Press:  28 April 2020

I.R. De Oliveira ,
P.A.S. Do Prado-Lima  and
B. Samuel-Lajeunesse
I.R. De Oliveira
Affiliation:
Clinique des Maladies Mentales et de l'Encéphale, 100, rue de la Santé, 75014Paris, France Departamento de Farmacologia e Fisiologia, ICS, Universidade Federal da Bahia, Vale do Canela, 40.140, Salvador, Brazil
P.A.S. Do Prado-Lima
Affiliation:
Clinique des Maladies Mentales et de l'Encéphale, 100, rue de la Santé, 75014Paris, France
B. Samuel-Lajeunesse
Affiliation:
Clinique des Maladies Mentales et de l'Encéphale, 100, rue de la Santé, 75014Paris, France
Get access

Summary

Part II of this paper contains some general considerations on tricyclic antidepressant (TCA) monitoring. Long-term assessment of TCA plasma levels is advised by the few existent studies, although each of these focusses on different aspects. Cardiovascular and central nervous system toxicity is reviewed as well as pharmacokinetics and the importance of protein binding. Some consideration is also given to their use in elderly patients. The authors conclude that although available data support its usefulness in many situations, routine measurement of TCA levels is not warranted.

Résumé

Résumé

La deuxième partie de cet article porte quelques considérations générales concernant le monitorage des antidépresseurs tricycliques (ADT). Les dosages des taux plasmatiques à long-terme sont conseillés par les rares études disponibles, bien que chaque étude porte sur des aspects différents du sujet. Nous présentons une revue concernant la toxicité cardiovasculaire et du système nerveux central. La pharmacocinétique et l'importance de la liaison aux protéines plasmatiques sont aussi discutées. Nous discutons l'usage des ADT chez les patients déprimés âgés. Les auteurs de cet article concluent que le monitorage de routine des ADT n ‘est pas indispensable, bien que les données disponibles soutiennent leur indication dans certaines situations.

Keywords

tricyclic antidepressantsplasma levelslong-term monitoringpharmacokineticspharmacogeneticsantidépresseurs tricycliquestaux plasmaliquesmonitorage à long-termepharmacocinétiquepharmacogénétique
Type
Original article
Information
Psychiatry and Psychobiology , Volume 4 , Issue 2 , 1989 , pp. 81 - 90
Copyright
Copyright © European Psychiatric Association 1989

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alexanderson, B.Evans, D.A.P. & Sjöqvist, F. (1979) Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br. Med. J. 4, 764–768CrossRefGoogle Scholar
Altamura, A.C. & Mauri, M. (1985) Plasma concentrations, information and adherence during long-term treatment with antidepressants. Br. J. Clin. Pharmacol. 20, 714–716CrossRefGoogle ScholarPubMed
Alvan, G. (1978) Individual differences in the disposition of drugs metabolized in the body. Clin. Pharmacokinet. 3, 155–175CrossRefGoogle Scholar
Amsterdam, J.D.Brunswick, D.I. & Potter, E. (1985) Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Arch. Gen. Psychiatry 42, 361–364CrossRefGoogle ScholarPubMed
Asberg, M.Cronholm, B. & Sjöqvist, F. (1970) Correlation of subjective side effects with plasma concentrations of nortriptyline. Br. Med. J. 4, 18–21CrossRefGoogle ScholarPubMed
Bailey, D.N.Van Dyke, C.Langou, R.A. & Jatlow, P.I. (1978) Tricyclic antidepressants: plasma levels and clinical findings in overdose. Am. J. Psychiatry 135, 1325–1328Google ScholarPubMed
Balant-Gorgia, A.E.Balant, L. & Zysset, T. (1987) High plasma concentrations of desmethylclomipramine after chronic administration of clomipramine to a poor metabolizer. Eur. J. Clin. Pharmacol. 32, 101–102CrossRefGoogle ScholarPubMed
Barré, J.Chamouard, J.M. & Houin, G. (1985) Equilibrium dialysis, ultrafiltration and ultracentrifugation compared for determining the plasma protein- binding characteristics of valproic acid. Clin. Chem. 31, 60–64CrossRefGoogle ScholarPubMed
Baumann, P. (1986) New aspects in research on blood levels and biovailability of antidepressants. Psychopathology 19 (suppl. 2), 79–84CrossRefGoogle Scholar
Baumann, P.Jonzier-Perey, M. & Koeb, L. (1986) Amitriptyline pharmacokinetics and clinical response I. Free and total plasma amitriptyline and nortriptyline. Int. Clin. Psychopharmacol. 1, 89–101CrossRefGoogle ScholarPubMed
Bertilsson, L.Mellstrom, B. & Sjoqvist, F. (1981) Slow hydroxylation of nortriptyline and concomitant pool debrisoquine hydroxylation: clinical implications, Lancet i, 560–561CrossRefGoogle Scholar
Bhanji, S. & Lader, M. (1977) The electroencephalographic and psychological effects of imipramine in depressed inpatients. Eur. J. Clin. Pharmacol. 12, 349–354CrossRefGoogle ScholarPubMed
Biggs, J.T.Spiker, D.G. & Petit, J.M. (1977) Tricyclic antidepressant overdose: incidence of symptoms. J. Am. Med. Assoc. 238, 135–138CrossRefGoogle ScholarPubMed
Braithwaite, R.A.Goulding, R. & Theano, G. (1972) Plasma concentration of amitriptyline and clinical response. Lancet i, 1297–1300CrossRefGoogle Scholar
Braithwaite, R.Montgomery, S. & Dawling, S. (1978) Nortriptyline in depressed patients with high plasma levels: II. Clin. Pharmacol. Ther. 29, 303–308CrossRefGoogle Scholar
Brcyer-Pfaff, U.Gaertner, H.J. & Kreuter, F. (1982) Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology 76, 240–244CrossRefGoogle Scholar
Burch, J.E.Ahmed, O. & Hullin, R.P. (1988) Antidepressive effect of amitriptyline with plasma drug levels controlled within three different ranges. Psychopharmacology 94, 197–205CrossRefGoogle ScholarPubMed
Cooper, T.B.Bark, N. & Simpson, G. (1981) Prediction of steady-state plasma and saliva levels of desmethylimipramine using a single dose, single time point procedure. Psychopharmacology 74, 115–121CrossRefGoogle ScholarPubMed
Cooper, T.B.Simpson, G.N. & Lee, J.H. (1976) Thymoleptic and neuroleptic drug plasma levels in psychiatry: current status. Int. Rev. Neuroblol. 19, 269–309CrossRefGoogle ScholarPubMed
Coppen, A. & Rama Rao, V.A. (1979) Amitriptyline and its demethylation rate. Lancet i, 49CrossRefGoogle Scholar
Corona, G.L.Fenoglio, L. & Pinelli, P. (1977) Amitriptyline—nortriptyline plasma levels and therapeutic response in depressed women. Pharmako-psychiatry 10, 299–308Google ScholarPubMed
Cluter, N.R.Zavadil III, A.P. & Eisdorfer, C. (1981) Concentrations of desipramine in elderly women. Am..1. Psychiatry 138, 1235–1237Google Scholar
Danon, A. & Chen, Z. (1979) Binding of imipramine to plasma proteins: effect of hyperlipoproteinemia. Clin. Pharmacol. Ther. 25, 316–321CrossRefGoogle ScholarPubMed
Dessain, B.C.Schatzberg, A.F. & Woods, B.T. (1986) Maprotiline treatment in depression. A perspective on seizures. Arch. Gen. Psychiatry 43, 86–90CrossRefGoogle ScholarPubMed
Devane, C.L.Wolin, R.E. & Rover, R.A. (1981) Excessive plasma concentrations of tricyclic antidepressants resulting from usual doses: a report of six cases. J. Clin. Psychiatry 42, 143–147Google ScholarPubMed
Edelbroek, P.M.Zitman, F.G. & Schreudr, J.N. (1984) Amitriptyline metabolism in relation to antidepressive effect. Clin. Pharmacol. Ther. 35, 467–473CrossRefGoogle ScholarPubMed
Faravelli, CBallerini, A.Broadhurst, A.D. & Das, M. (1982) Relevance of plasma levels during clomipramine treatment of primary depression. J. Affect. Disord. 4, 163–165CrossRefGoogle ScholarPubMed
Faravelli, CBroadhurst, A.D. & Ambonetti, A. (1983) Double-blind trial with oral versus intravenous clomipramine in primary depression. Biol. Psychiatry 18, 695–706Google ScholarPubMed
Garvey, M.J.Tuason, V.B. & Johnson, R.A. (1984) Elevated plasma tricyclic levels with therapeutic doses of imipramine. Am. J. Psychiatry 141, 853–856Google ScholarPubMed
Geller, B.Perel, J.M. & Knitter, E.F. (1983) Nortriptyline in major depressive disorder in children: response, steady-state plasma levels, predictive kinetics and pharmacokinetics. Psychopharmacol. Bull. 19, 62–65Google Scholar
Glassman, A.H. & Bigger, J.T. Jr (1981) Cardiovascular effects of therapeutic doses of tricyclic antidepressants. Arch. Gen. Psychiatry 38, 815–820CrossRefGoogle ScholarPubMed
Glassman, A.H.Roose, S.P. & Giardina, E.G.V. (1987) Cardiovascular effects of tricyclic antidepressants. In: Psychopharmacology: The Third Generation of Progress (Meltzer, H.Y., ed.), Raven Press, New York, pp. 1437–1442Google Scholar
Gram, L.F.Reisby, N. & Ibsen, I. (1976) Plasma levels and antidepressive effect of imipramine. Clin. Pharmacol. Ther. 19, 318–324CrossRefGoogle ScholarPubMed
Gram, L.F.Sondergaard, I. & Christiansen, J. (1977) Steady-state kinetics of imipramine in patients. Psychopharmacology 54, 255–261CrossRefGoogle ScholarPubMed
Oreenblatt, D.J.Sellers, E.M. & Koch-Weser, J. (1982) Importance of protein binding for the interpretation of serum or plasma drug concentrations. J. Clin. Pharmacol. 22, 259–263CrossRefGoogle Scholar
Hammer, W. & Sjöcqvist, F. (1967) Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life. Sei. 6, 1895–1903CrossRefGoogle ScholarPubMed
Holliday, W.Brasfield, K.H. & Powers, B. (1982) Grand mal seizures induced by maprotiline. Am. J. Psychiatry 139, 673–674Google ScholarPubMed
Irwin, P. & Fink, M. (1978) Electroencephalogram study of mianserin in depressed patients. Br. J. Clin. Pharmacol. 5, 43s–47sGoogle ScholarPubMed
Jungkunz, G. & Kuss, H.J. (1978) Amitriptyline and its demethylation rate. Lancet ii, 1263–1264CrossRefGoogle Scholar
Jungkunz, G. & Kuss, H.J. (1980) On the relationship of nortriptyline/amitriptyline ratio lo clinical improvement of amitriptyline treated patients. Phurmako-psychiatry 13, 111–116Google Scholar
Kragh-Sørensen, P.Hansen, C. & Larsen, N.B. (1974) Long-term treatment of endogenous depression with nortryptiline with control of plasma levels. Psychol. Med. 4, 174–180CrossRefGoogle Scholar
Kragh-Sørensen, P.Hvidberg, E.F. & Hansen, C. (1976) Therapeutic control of plasma concentrations and long-term effect of nortriptyline in recurrent affective disorders. Pharmakopsychiutry 9, 178–182CrossRefGoogle ScholarPubMed
Kumar, V.Smith, R.C. & Reed, K. (1987) Plasma levels and effects of nortriptyline in geriatric depressed patients. Acta Psychiatr. Scand. 75, 20–28CrossRefGoogle ScholarPubMed
Lôo, H.Benyacoub, A.K. & Rovei, V. (1980) Long-term monitoring of tricyclic antidepressant plasma concentrations. Br. J. Psychiatry 137, 444–451CrossRefGoogle ScholarPubMed
Mahgoub, A.Idle, J.R. & Dring, L.G. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet ii, 584–586CrossRefGoogle Scholar
Matuzas, W.Javaid, J.I. & Uhlenhuth, E.H. (1983) Plasma and red blood cell imipramine levels and clinical response among depressed outpatients. Psychopharmacol. Hull. 19, 652–654Google Scholar
Mellstrom, B.Bertilsson, L. & Träksman, L. (1979) Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients. Pharmacology 19, 282–287CrossRefGoogle Scholar
Moyes, I.CA.Ray, R.L. & Moyes, R.B. (1980) Plasma levels and clinical improvement-a comparative study of clomipramine and amitriptyline in depression. Postgrad. Med. J. 56 (suppl. 1), 127–129Google Scholar
Molnar, G. & Gupta, R.N. (1980) Plasma levels and tricyclic antidepressant therapy. 11. Pharmacokinetics, clinical and toxicologic aspects. Biopharm. Drug Dispos. 1, 283–305CrossRefGoogle Scholar
Muscettola, O.Goodwin, F.K. & Potter, W.Z. (1978) Imipramine and desipramine in plasma and spinal fluid : relationship to clinical response and serotonin metabolism. Arch, Gen. Psychiatry 35, 621–625CrossRefGoogle ScholarPubMed
Nagy, A. & Johansson, R. (1977) The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. Psychopharmacology 54, 125–131CrossRefGoogle ScholarPubMed
Nebert, D.W. (1979) Multiple forms of inductible drugmetabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity. Mol. Cell. Biochem. 27, 27–46CrossRefGoogle Scholar
Nelson, J.C.Jatlow, P.I. & Mazure, C. (1985) Desipramine plasma levels and response in elderly melancholic patients. J. Clin. Psychopharmacol. 5, 217–220CrossRefGoogle ScholarPubMed
Nelson, J.C.Jatlow, P. & Quintan, D.M. (1982) Desipramine plasma concentration and antidepressant response. Arch. Gen. Psychiatry 39, 1419–1422CrossRefGoogle ScholarPubMed
Nies, A.Robinson, D. & Friedman, M. (1977) Relationship between age and tricyclic antidepressant plasma levels. Am, J. Psychiatry 134, 790–793Google ScholarPubMed
Olivier, J.Martin, R.Marzin, D. & Lacassin, J. (1974) Une étude pharmacocliniquc du traitement par l'imipramine. J. Pharmacol, din. 1, 233–236Google Scholar
Orsulac, P.J. & Schildkraut, J.J. (1979) Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels. Ther. Drug Monit. 1, 199–208CrossRefGoogle Scholar
Perry, P.J.Browne, J.L. & Alexander, B. (1985) Relation ship of free nortriptyline levels to therapeutic response. Acta Psychiatr. Stand. 72, 120–125CrossRefGoogle Scholar
Petit, J.M.Spiker, D.G. & Ruwitch, J.F. (1977) Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin.Pharmacol. Ther. 21, 47–51Google ScholarPubMed
Piafsky, K.M. & Borga, O. (1977) Plasma protein binding of basic drugs. II. Importance of alpha-1-acid glycoprotein for interindividual variation. Clin. Pharmacol. Ther. 22, 545–549CrossRefGoogle ScholarPubMed
Potter, W.Z.Calil, H.M. & Manian, A.A. (1979) Hydroxylated metabolites of tricyclic antidepressants : preclinical assessement of activity, Biol. Psychiatry 14 601–613Google Scholar
Potter, W.Z.Zavadil III, A.P. & Kopin, I.J. (1980) Single-dose kinetics predict steady-state concentrations of imipramine and desipramine. Arch. Gen. Psychiatry 37, 314–320CrossRefGoogle ScholarPubMed
Preskorn, S.H. & Irwin, H.A. (1982) Toxicity of tricyclic antidepressants - kinetics, mechanism, intervention: a review. J. Clin. Psychiatry 43, 151–156Google ScholarPubMed
Preskorn, S.H.Othmer, S. & Lai, C. (1984) Tricyclic induced EEG abnormalities and plasma drug concentrations. J. Clin. Psychopharmacol. 4, 262–265CrossRefGoogle ScholarPubMed
Preskorn, S.H. & Simpson, S. (1983) Tricyclic antidepressant induced delirium and plasma drug concentration. Am. J. Psychiatry 139, 822–823Google Scholar
Reed, K.Smith, R. & Schooler, J.C. (1980) Cardiovascular effects of nortriptyline in geriatric patients. Am. J. Psychiatry 137, 986–989Google ScholarPubMed
Rigal, J.G.Albin, H.C. & Duchier, A.R. (1987) Imipranmine blood levels and clinical outcome. J. Clin. Psychopharmacol. 7, 222–259CrossRefGoogle ScholarPubMed
Risch, S.C.Kalin, N.H. & Janowsky, D.S. (1981) Indications and guidelines for plasma tricyclic antidepressant concentration monitoring. J. Clin. Psychopharmacol. 1, 59–63CrossRefGoogle ScholarPubMed
Robinson, D.S.Cooper, T.B. & Ravaris, C.L. (1979) Plasma tricyclic drug levels in amitriptyline-treated depressed patients. Psychopharmacology 6, 223–231CrossRefGoogle Scholar
Routledge, P.A. (1986) The plasma protein binding of basic drugs. Br. J. Clin. Pharmacol. 22, 499–506CrossRefGoogle ScholarPubMed
Rudorfer, M.V. & Potter, W.Z. (1987) Pharmacokinetics of antidepressants. In: Psychopharmacology: The Third Generation of Progress (Meltzer, H.Y., ed.), Raven Press, New York, pp. 1353–1363Google Scholar
Smith, R.C.Reed, K. & Leelavathi, D.E. (1980) Pharmacokinetics and the effects of nortriptyline in geriatric depressed patients. Psychopharmacol. Bull. 16, 54–57Google ScholarPubMed
Snyder, S.H. & Yamamura, H.T. (1977) Antidepressants and muscarinic acethylcholine receptor. Arch. Gen. Psychiatry 34, 236–239CrossRefGoogle Scholar
Sørensen, B.Kragh-Sørensen, P. & Larsen, N.E. (1978) The practical significance of nortriptilinc plasma control. Psychopharmacology 59, 35–39CrossRefGoogle ScholarPubMed
Spiker, G.D.Weiss, A.N. & Chang, S.S. (1975) Tricyclic antidepressant overdose: clinical presentation and plasma levels. Clin. Pharmacol. Ther. 18, 539–546CrossRefGoogle ScholarPubMed
Tinguely, D.Baumann, P. & Conti, M. (1985) Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of the alpha-1-acid glycoprotein. Eur. J. Clin. Pharmacol. 27, 661–666CrossRefGoogle ScholarPubMed
Tollefson, G.Valentine, R. & Garvey, M. (1985) Imipramine metabolism in recurrent depressive episodes. J. Affect. Dis. 8, 183–186CrossRefGoogle ScholarPubMed
Träksman, L.Asberg, M. & Bertilsson, L. (1979) Plasma levels of clomipramine and its desmethyl metabolite during treatment of depression. Clin. Pharmacol. Ther. 26, 600–610Google Scholar
Van Brunt, N. (1983) The clinical utility of tricyclic antidepressant blood levels: a review of the literature. Ther. Drug. Monit. 5, 1–10CrossRefGoogle ScholarPubMed
Vandel, S.Vandel, B. & Sandoz, M. (1978) Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur. J. Clin. Pharmacol. 14, 185–190CrossRefGoogle ScholarPubMed
Young, R.C.Alexopoulos, G.S. & Shamoian, C.A. (1984) Plasma 10-hydroxy nortriptyline in elderly depressed patients. Clin. Pharmacol. Ther. 35, 540–544CrossRefGoogle Scholar
Ziegler, V.E.Clayton, P.J. & Biggs, J.T. (1977) A comparison study of amitriptyline and nortriptyline with plasma levels. Arch. Gen. Psychiatry 34, 607–612CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.